key: cord-0836806-el9f65zh
authors: Laursen, Stig B.; Gralnek, Ian M.; Stanley, Adrian J.
title: Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic
date: 2020-09-23
journal: Endoscopy
DOI: 10.1055/a-1202-1374
sha: d1a0a0130a700638fdef913aedb7ef3c9c23e9a7
doc_id: 836806
cord_uid: el9f65zh

nan

Upper gastrointestinal bleeding (UGIB) is a common cause of hospital admissions worldwide. While health care systems are under significant strain during the COVID-19 pandemic, it is logical to reduce hospital admissions for patients at very low risk of poor outcomes. Additionally, upper gastrointestinal endoscopy is recognized as an aerosol-generating procedure that should be restricted during the pandemic, because of the risk of spreading COVID-19 and the limited availability of personal protection equipment [1, 2] . Therefore, elective and even urgent endoscopy has been suspended in many centers worldwide. Current guidelines recommend the use of the Glasgow-Blatchford Score (GBS) for predicting the need for hospital-based intervention in patients with UGIB [3, 4] . Patients with GBS ≤ 1 are recognized to be at very low risk and can safely be managed as outpatients with no need for inpatient endoscopy [3, 4] . Based on data from a large international multicenter study including 3012 consecutive patients with UGIB [5] , we have evaluated the outcomes associated with extended low risk GBS thresholds for identifying patients needing hospital admission and endoscopic therapy.

▶ Table 1 shows the numbers of identified low-risk patients and outcomes for GBS thresholds 0 to ≤ 5. Use of GBS ≤ 2 or ≤ 3 as thresholds for avoiding hospital admission in UGIB would lead to avoidance of admission and in-hospital endoscopy in 26 % -32 % of all UGIB patients. In patients classified as being at low risk, the risk of needing endoscopic therapy (3.3 % -4.1 %), needing surgery or embolization (0.5 %), death within 30 days (0.8 % -1.7 %), and delayed identification of upper gastrointestinal cancer (0.65 % -0.75 %) would probably be acceptable in countries with a health care system facing significant strain or potential collapse from COVID-19. If such patients are admitted for other reasons, the very low risk of needing endoscopic therapy suggests endoscopy could be undertaken electively as an outpatient. Consistently with these suggested thresholds, re-analysis of data from a multicenter study of 1555 patients with UGIB found endoscopic therapy was required in 4.2 % -4.4 % patients with GBS 2 or 3, but rose to 9.4 % for GBS 4 [6] . Combining extended GBS thresholds with exclusion of patients with major risk factors including systolic blood pressure < 100 mmHg, syncope, or liver cirrhosis was not superior to use of GBS ≤ 2 -3 alone. However, clinical judgment would still be required for specific patients. In countries severely affected by COVID-19, we suggest that the low risk threshold for defining UGIB patients who require hospitalization and inpatient endoscopy could be raised to GBS ≤ 2 or even GBS ≤ 3. These patients could be treated with high dose oral proton pump inhibitors and evaluated with endoscopy once the epidemic has peaked. 

Updated on: 03

ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

Management of nonvariceal upper gastrointestinal bleeding: Guideline recommendations from the International Consensus Group

Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study

Multicentre comparison of the Glasgow Blatchford and Rockall scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage